Breathe, breathe in the air: the anti-CCN2 antibody pamrevlumab (FG-3019) completes a successful phase II clinical trial for idiopathic pulmonary fibrosis
Crossref DOI link: https://doi.org/10.1007/s12079-019-00542-6
Published Online: 2019-12-07
Published Print: 2019-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Leask, Andrew
Text and Data Mining valid from 2019-12-01
Version of Record valid from 2019-12-01
Article History
First Online: 7 December 2019